The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A first-in-human phase 1 trial of NX-2127, a first-in-class oral BTK degrader with IMiD-like activity, in patients with relapsed and refractory B-cell malignancies.
 
Anthony Mato
Consulting or Advisory Role - Abbvie/Genentech; Acerta Pharma/AstraZeneca; Adaptive Biotechnologies; Bristol-Myers Squibb/Pfizer; Celgene; Curio/Vaniam Group; DTRM; Johnson & Johnson; Loxo/Lilly; Merck; Pharmacyclics; TG Therapeutics; Verastem
Research Funding - Abbvie/Genentech; Acerta Pharma/AstraZeneca; Adaptive Biotechnologies; DTRM; Genmab; Johnson & Johnson; LOXO; Nurix; Pharmacyclics; Regeneron; Sunesis Pharmaceuticals; TG Therapeutics
 
Alexey Valeryevich Danilov
Stock and Other Ownership Interests - Abbvie
Honoraria - Curio Science; Dava Oncology
Consulting or Advisory Role - Abbvie; AstraZeneca; Bayer; BeiGene; Bristol-Myers Squibb; Gamida Cell; Genentech/Roche; Lilly; MorphoSys; Pharmacyclics/Janssen; Secura Bio; TG Therapeutics
Research Funding - AstraZeneca; Bayer; Bristol-Myers Squibb; MEI Pharma; Secura Bio; Takeda; TG Therapeutics
 
Manish R. Patel
Leadership - ION Pharma
Honoraria - Adaptive Biotechnologies; Bayer; Genentech; Janssen Oncology; Pfizer; Pharmacyclics
Consulting or Advisory Role - Pfizer/EMD Serono; Pharmacyclics/Janssen
Speakers' Bureau - Celgene; Exelixis; Genentech/Roche; Taiho Pharmaceutical
Research Funding - Acerta Pharma (Inst); ADC Therapeutics (Inst); Agenus (Inst); Aileron Therapeutics (Inst); Artios (Inst); Artios (Inst); AstraZeneca (Inst); Bayer (Inst); Bicycle Therapeutics (Inst); BioNTech (Inst); BioTheryX (Inst); Black Diamond Therapeutics (Inst); Boehringer Ingelheim (Inst); Calithera Biosciences (Inst); Celgene (Inst); Checkpoint Therapeutics (Inst); CicloMed (Inst); Clovis Oncology (Inst); Curis (Inst); cyteir (Inst); Daiichi Sankyo (Inst); eFFECTOR Therapeutics (Inst); EMD Serono (Inst); Erasca, Inc (Inst); Erasca, Inc (Inst); Evelo Therapeutics (Inst); FORMA Therapeutics (Inst); Genentech/Roche (Inst); Gilead Sciences (Inst); GlaxoSmithKline (Inst); H3 Biomedicine (Inst); Hengrui Therapeutics (Inst); Hutchison MediPharma (Inst); IgM Biosciences (Inst); IgM Biosciences (Inst); Ignyta (Inst); Incyte (Inst); Jacobio (Inst); Janssen (Inst); Jounce Therapeutics (Inst); Klus Pharma (Inst); Kymab (Inst); Lilly (Inst); Loxo (Inst); LSK BioPharma (Inst); Lycera (Inst); MabSpace Biosciences (Inst); Macrogenics (Inst); Merck (Inst); Millennium (Inst); Mirati Therapeutics (Inst); Moderna Therapeutics (Inst); NGM Biopharmaceuticals (Inst); Novartis (Inst); nurix (Inst); ORIC Pharmaceuticals (Inst); Pfizer (Inst); Phoenix Molecular Designs (Inst); Placon (Inst); Portola Pharmaceuticals (Inst); Prelude Therapeutics (Inst); PubGene (Inst); PureTech (Inst); PureTech (Inst); Puretech (Inst); QiLu Pharmaceutical (Inst); Relay Therapeutics (Inst); Revolution Medicines (Inst); Ribon Therapeutics (Inst); Samumed (Inst); Seven and Eight Biopharmaceuticals (Inst); Silicon Therapeutics (Inst); Stemline Therapeutics (Inst); Syndax (Inst); Synthorx (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst); TeneoBio (Inst); Tesaro (Inst); TopAlliance BioSciences Inc (Inst); Treadwell Therapeutics (Inst); Treadwell Therapeutics (Inst); Vedanta Biosciences (Inst); Verastem (Inst); Vigeo Therapeutics (Inst); Xencor (Inst); Zymeworks (Inst)
 
Michael Timothy Tees
No Relationships to Disclose
 
Ian W. Flinn
Consulting or Advisory Role - Abbvie (Inst); AstraZeneca (Inst); BeiGene (Inst); Century Therapeutics (Inst); Genentech (Inst); Genmab (Inst); Gilead Sciences (Inst); Great Point Partners (Inst); Hutchison MediPharma (Inst); Iksuda Therapeutics (Inst); Innocare (Inst); Janssen (Inst); Juno Therapeutics (Inst); Kite, a Gilead company (Inst); MorphoSys (Inst); Novartis (Inst); Nurix (Inst); Pharmacyclics (Inst); Roche (Inst); Seagen (Inst); SERVIER (Inst); Shanghai Yingli Pharmaceuticals (Inst); Takeda (Inst); TG Therapeutics (Inst); Unum Therapeutics (Inst); Verastem (Inst); Vincerx Pharma (Inst)
Research Funding - Abbvie (Inst); Acerta Pharma (Inst); Agios (Inst); ArQule (Inst); AstraZeneca (Inst); BeiGene (Inst); Bio-Path Holdings, Inc (Inst); Bristol-Myers Squibb (Inst); CALGB (Inst); CALIBR (Inst); Celgene (Inst); City of Hope (Inst); Constellation Pharmaceuticals (Inst); CTI (Inst); Curis (Inst); Fate Therapeutics (Inst); FORMA Therapeutics (Inst); Forty Seven (Inst); Genentech (Inst); Gilead Sciences (Inst); IGM Biosciences (Inst); Incyte (Inst); Infinity Pharmaceuticals (Inst); Innocare (Inst); Janssen (Inst); Kite, a Gilead company (Inst); Loxo (Inst); Merck (Inst); Millennium (Inst); MorphoSys (Inst); Myeloid Therapeutics (Inst); Novartis (Inst); Nurix (Inst); Pfizer (Inst); Pharmacyclics (Inst); Portola Pharmaceuticals (Inst); Rhizen Pharmaceuticals (Inst); Roche (Inst); Seagen (Inst); TCR2 Therapeutics (Inst); Tessa Therapeutics (Inst); TG Therapeutics (Inst); Triact Therapeutics (Inst); Trillium Therapeutics (Inst); Unum Therapeutics (Inst); Verastem (Inst)
 
Weiyun Z. Ai
Honoraria - Acrotech Biopharma; ADC Therapeutics; BeiGene; Kite, a Gilead Company; Kymera; Walking Fish Therapeutics
Research Funding - Nurix
 
Krish Patel
Consulting or Advisory Role - Abbvie; ADC Therapeutics; AstraZeneca; BeiGene; Bristol-Myers Squibb/Celgene/Juno; Epizyme; Genentech; Kite, a Gilead company; Loxo/Lilly; Morphosys; Pharmacyclics; Seagen; TG Therapeutics
Speakers' Bureau - AstraZeneca; Bristol-Myers Squibb/Celgene; Kite, a Gilead company; TG Therapeutics
Research Funding - Aptevo Therapeutics (Inst); AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Curis (Inst); Epizyme (Inst); Fate Therapeutics (Inst); Kite/Gilead (Inst); Loxo/Lilly (Inst); MEI Pharma (Inst); Nurix (Inst); Pharmacyclics (Inst); Roche/Genentech (Inst); Takeda (Inst); Trillium Therapeutics (Inst); Xencor (Inst)
 
Michael Wang
Honoraria - Acerta Pharma; AstraZeneca; BeiGene; Breast-Gynecological International Cancer Society; CAHON; Chinese Anti-Cancer Association; Chinese Medical Association; Clinical Care Options; Dava Oncology; Epizyme; Hebei Cancer Prevention Federation; Imedex; Janssen Research & Development; Kite, a Gilead company; Miltenyi Biomedicine; Moffit Cancer Center; Mumbai Hematology Group; Newbridge Pharmaceuticals; OM Pharmaceutical Industries; Pharmacyclics/Janssen; Physicans' Education Resource; Scripps Health; The First Affiliated Hospital of Zhejiang University
Consulting or Advisory Role - AstraZeneca; Bayer; BeiGene; Bioinvent; CStone Pharmaceuticals; DTRM; Epizyme; Genentech; Guidepoint Global; Innocare; Janssen Research & Development; Juno Therapeutics; Kite, a Gilead company; Loxo; Miltenyi Biomedicine; Oncternal Therapeutics; Pharmacyclics/Janssen; Pulse Biosciences; VelosBio
Research Funding - Acerta Pharma; AstraZeneca; BeiGene; Bioinvent; Celgene; Innocare; Janssen Research & Development; Juno Therapeutics; Kite, a Gilead company; Lilly; Loxo; Molecular Templates; Oncternal Therapeutics; Pharmacyclics; VelosBio
Travel, Accommodations, Expenses - AstraZeneca; Celgene; Dava Oncology; Janssen Research & Development; OM Pharmaceutical Industries
 
Susan M. O'Brien
Consulting or Advisory Role - Abbvie; Acerta Pharma; Alexion Pharmaceuticals; Alliance Pharma; Amgen; Aptose Biosciences; Astellas Pharma; AstraZeneca; Autolus; BeiGene; Bristol-Myers Squibb; Caribou Biosciences; Celgene; Dynamed; Gilead Sciences; GlaxoSmithKline; Janssen Oncology; Johnson & Johnson; Juno Therapeutics; Kite, a Gilead Company; Lilly; Loxo; MEI Pharma; Merck; MustangBio; Nova Research Company; Nurix; Pfizer; Pharmacyclics; Regeneron; TG Therapeutics; Vaniam Group; Verastem; Vida Ventures
Research Funding - Abbvie; Acerta Pharma; Alexion Pharmaceuticals; Amgen; Aptose Biosciences; Astellas Pharma; AstraZeneca; Autolus; BeiGene; Bristol-Myers Squibb; Caribou Biosciences; Celgene; Dynamed; Gilead Sciences; GlaxoSmithKline; Janssen Oncology; Johnson & Johnson; Juno Therapeutics; Kite, a Gilead Company; Lilly; Loxo; MEI Pharma; Merck; MustangBio; Nova Research Company; Nurix; Pfizer; Pharmacyclics; Regeneron; TG Therapeutics; Vaniam Group; Verastem; Vida Ventures
 
Srinand Nandakumar
Employment - Allogene Therapeutics
Stock and Other Ownership Interests - Allogene Therapeutics; Biomarin; Crispr Therapeutics; Novocure; Seagen
 
May Tan
Employment - Nurix
Stock and Other Ownership Interests - Nurix
Patents, Royalties, Other Intellectual Property - Nurix
 
Erin Meredith
Employment - Nurix
Stock and Other Ownership Interests - Nurix
 
Melissa Gessner
Employment - Nurix
Stock and Other Ownership Interests - Nurix
 
Su Young Kim
Employment - Abbvie
Stock and Other Ownership Interests - Abbvie
 
Adrian Wiestner
Honoraria - Elsevier
Research Funding - Acerta Pharma; Genmab; Merck; Nurix; Pharmacyclics; Verastem
Patents, Royalties, Other Intellectual Property - Zap70 in CLL; Anti-C3d antibodies
 
William G. Wierda
Consulting or Advisory Role - Sanofi
Research Funding - Abbvie; Acerta Pharma; Cyclacel; Genentech; Gilead Sciences; GlaxoSmithKline/Novartis; Janssen; Juno Therapeutics; Kite, a Gilead company; Loxo; miRagen; Oncternal Therapeutics, Inc; Pharmacyclics; Sunesis Pharmaceuticals; Xencor